Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA polymerase II mediator complex subunit 12 (MED12) is a critical component of the Mediator complex, a multi-protein assembly that bridges gene-specific transcription factors to the RNA polymerase II initiation machinery [1, 9]. It serves as the central architectural subunit of the Mediator kinase module, where it acts as an essential allosteric activator for the kinases CDK8 and CDK19 [7, 11]. Through these interactions, MED12 plays a fundamental role in regulating the transition between transcriptional initiation and elongation, as well as maintaining cell-type-specific gene expression programs [10, 13]. Beyond its nuclear functions, MED12 also operates in the cytoplasm to modulate TGF-beta receptor signaling by regulating receptor maturation and surface expression [6]. Clinically, MED12 is highly significant due to its frequent mutation in both benign and malignant neoplasms, most notably in over 70% of uterine leiomyomas and a high percentage of breast phyllodes tumors [1, 17]. Germline mutations in the MED12 gene are responsible for several X-linked intellectual disability syndromes, including Opitz-Kaveggia and Lujan-Fryns syndromes [12, 16]. In the context of oncology, MED12 is a major determinant of therapeutic response; its loss or dysregulation is a known driver of resistance to targeted therapies such as EGFR, ALK, and BRAF inhibitors [2, 6]. Because of its central role in oncogenic signaling and drug resistance, MED12 is an emerging therapeutic target and a potential predictive biomarker for precision medicine [2, 3].
MED12 acts as an allosteric activator of the CDK8/CDK19 kinase module within the Mediator complex and serves as a physical bridge between transcription factors and RNA polymerase II to regulate the initiation and re-initiation of transcription.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA polymerase II mediator complex subunit 12 (MED12).